Ultime notizie per Prestige Consumer (NYSE:PBH) Azioni

Prestige Consumer

Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer Healthcare Inc

Pathfinder Bancorp Inc

PARAMOUNT BED CO ORD by Paramount Bed Co., Ltd.

Paramount Bed Holdings Co Ltd

PBS Holding Inc

PALIBURG HOLDINGS LTD by PALIBURG HOLDINGS LTD.

Paliburg Holdings Ltd

A large exercise of company stock options by Adel Mekhail, EVP at Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) was disclosed in a new SEC filing on November 15, as part of an insider exercise.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001295947/000110465924119387//Archives/edgar/data/1295947/000110465924119387/0001104659-24-119387-index.htm">U.S. Securities and Exchange Commission</a> on Friday revealed that Mekhail, EVP at Prestige Consumer in the Health Care sector, exercised stock options for 5,565 shares of PBH stock. The exercise price of the options was $44.33 per share.
Prestige Consumer shares are trading down 0.0% at $82.79 at the time of this writing on Friday morning. Since the current price is $82.79, this makes Mekhail's 5,565 shares worth $214,029.
<h3>All You Need to Know About Prestige Consumer</h3>
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
<h3>Understanding the Numbers: Prestige Consumer's Finances</h3>
Revenue Growth: Prestige Consumer's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -0.88%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company shows a low gross margin of 55.46%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Prestige Consumer's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 1.1.
</li>
</ul>
Debt Management: Prestige Consumer's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.61.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 20.19 is lower than the industry average, implying a discounted valuation for Prestige Consumer's stock.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 3.74, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a lower-than-industry-average EV/EBITDA ratio of 14.33, Prestige Consumer presents a potential value opportunity, as investors are paying less for each unit of EBITDA.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001295947">Check Out The Full List Of Prestige Consumer's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Insider Trades

Trading Ideas

Options Exercise: Adel Mekhail At Prestige Consumer Realizes $214K

A significant insider transaction involving the exercise of company stock options was reported on November 15, by Christine Sacco, Chief Financial Officer at Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>), as per the latest SEC filing.
What Happened: In an insider options sale disclosed in a Form 4 filing on Friday with the <a href="https://www.sec.gov/Archives/edgar/data/0001295947/000110465924119388//Archives/edgar/data/1295947/000110465924119388/0001104659-24-119388-index.htm">U.S. Securities and Exchange Commission</a>, Sacco, Chief Financial Officer at Prestige Consumer, exercised stock options for 24,686 shares of PBH. The transaction value amounted to $1,289,349.
The Friday morning market activity shows Prestige Consumer shares down by 0.0%, trading at $82.79. This implies a total value of $1,289,349 for Sacco's 24,686 shares.
<h3>All You Need to Know About Prestige Consumer</h3>
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
<h3>Financial Insights: Prestige Consumer</h3>
Revenue Growth: Prestige Consumer's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -0.88%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Navigating Financial Profits:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 55.46%, indicating concerns regarding cost management and overall profitability relative to its industry counterparts.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Prestige Consumer exhibits below-average bottom-line performance with a current EPS of 1.1.
</li>
</ul>
Debt Management: Prestige Consumer's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.61.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 20.19 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 3.74, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Prestige Consumer's EV/EBITDA ratio, lower than industry averages at 14.33, indicates attractively priced shares.
</li>
</ul>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001295947">Check Out The Full List Of Prestige Consumer's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Christine Sacco At Prestige Consumer Capitalizes: Options Exercised, Resulting In $1.29M

DA Davidson analyst Linda Bolton Weiser maintains Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) with a Buy and maintains $95 price target.

Price Target

Analyst Ratings

DA Davidson Maintains Buy on Prestige Consumer, Maintains $95 Price Target

"We will continue to execute on our business model that is focused on long-term brand-building and leveraging our cash generation. With this proven strategy and strong balance sheet we are well positioned to maximize shareholder value through disciplined capital deployment," Mr. Lombardi concluded.
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Fiscal 2025 Outlook</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Revenue</td>
<td>$1,125 to $1,140 million</td>
</tr>
<tr>
<td>Organic Revenue Growth</td>
<td>Approximately 1%</td>
</tr>
<tr>
<td>Adjusted Diluted E.P.S.</td>
<td>$4.40 to $4.46</td>
</tr>
<tr>
<td>Free Cash Flow</td>
<td>$240 million or more</td>
</tr>
</tbody>
</table>
</figure>

Guidance

Prestige Consumer Affirms FY25 GAAP EPS Guidance Of $4.40-$4.46 vs $4.49 Est; Sales Of $1.13B-1.14B vs $1.14B Est

Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) reported quarterly earnings of $1.09 per share which beat the analyst consensus estimate of $1.08 by 0.93 percent. This is a 1.87 percent increase over earnings of $1.07 per share from the same period last year. The company reported quarterly sales of $283.785 million which beat the analyst consensus estimate of $282.093 million by 0.60 percent. This is a 0.88 percent decrease over sales of $286.316 million the same period last year.

Earnings

Earnings Beats

Prestige Consumer Q2 2025 Adj. EPS $1.09 Beats $1.08 Estimate, Sales $283.785M Beat $282.093M Estimate

Jefferies analyst Stephanie Wissink assumes Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) with a Hold rating and raises Price Target to $76.

Initiation

Jefferies Assumes Prestige Consumer at Hold, Raises Price Target to $76

DA Davidson analyst Linda Bolton Weiser maintains Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) with a Buy and raises the price target from $93 to $95.

DA Davidson Maintains Buy on Prestige Consumer, Raises Price Target to $95

DA Davidson analyst Linda Bolton Weiser maintains Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) with a Buy and maintains $93 price target.

DA Davidson Maintains Buy on Prestige Consumer, Maintains $93 Price Target

Prestige Consumer Healthcare Reaffirms FY25 Outlook For Sales Of $1.125B - $1.14B (Est $1.129B), Adjusted EPS Of $4.40 - $4.46 (Est $4.40)

Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) reported quarterly earnings of $0.90 per share which beat the analyst consensus estimate of $0.86 by 4.65 percent. This is a 15.09 percent decrease over earnings of $1.06 per share from the same period last year. The company reported quarterly sales of $267.142 million which beat the analyst consensus estimate of $260.414 million by 2.58 percent. This is a 4.36 percent decrease over sales of $279.309 million the same period last year.

Prestige Consumer Q1 2025 Adj. EPS $0.90 Beats $0.86 Estimate, Sales $267.142M Beat $260.414M Estimate

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Oppenheimer analyst Brian Nagel upgraded the rating for NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) from Perform to Outperform, while raising the price target from $110 to $120. Nike shares gained 0.8% to close at $95.57 on Thursday. <a href="https://www.benzinga.com/quote/NKE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley analyst Carlos De Alba upgraded Alcoa Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>) from Equal-Weight to Overweight and boosted the price target from $36.5 to $50. Alcoa shares gained 4% to close at $38.98 on Thursday. <a href="https://www.benzinga.com/quote/AA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital analyst Shagun Singh upgraded the rating for Outset Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) from Sector Perform to Outperform, while increasing the price target from $5 to $6. Outset Medical shares fell 1.5% to settle at $3.5850 on Thursday. <a href="https://www.benzinga.com/quote/OM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Carlos De Alba upgraded Freeport-McMoRan Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) from Equal-Weight to Overweight and boosted the price target from $49.5 to $62. Freeport-McMoRan shares gained 3.5% to close at $49.36 on Thursday. <a href="https://www.benzinga.com/quote/FCX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>DA Davidson analyst Linda Bolton Weiser upgraded the rating for Prestige Consumer Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) from Neutral to Buy, while raising the price target from $65 to $93. Prestige Consumer shares settled at $65.28 on Thursday. <a href="https://www.benzinga.com/quote/BVN/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/24/06/39431308/nvidia-applied-materials-and-2-other-stocks-insiders-are-selling">Nvidia, Applied Materials And 2 Other Stocks Insiders Are Selling</a>

Upgrades

Markets

This Nike Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

DA Davidson analyst Linda Bolton Weiser upgrades Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) from Neutral to Buy and raises the price target from $65 to $93.

DA Davidson Upgrades Prestige Consumer to Buy, Raises Price Target to $93

Canaccord Genuity analyst Susan Anderson maintains Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) with a Buy and maintains $80 price target.

Canaccord Genuity Maintains Buy on Prestige Consumer, Maintains $80 Price Target

Prestige Consumer Healthcare Inc.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pbh#NYSE">PBH</a>) delivered fourth-quarter fiscal 2024 earnings per share of $1.02, a 4.7% decline from the year-ago period&#39;s figure. The metric also missed the Zacks Consensus Estimate by 10.5%.
GAAP EPS for the quarter was 98 cents, a significant improvement from the year-ago loss of $4.78 per share.
For the full year, adjusted EPS was $4.21, flat year over year.
<h3>Revenues</h3>
Total revenues in the fiscal fourth quarter declined 3.1% year over year (down 2.9% on an organic basis) to $276.9 million and lagged the Zacks Consensus Estimate by 3.5%.
The disappointing revenue performance for the quarter was caused by supply chain pressure late in the fourth quarter that affected Prestige Consumer&#39;s ability to fulfill retailer orders.
Full-year revenues were $1.13 billion, unchanged from the fiscal 2023 level.
<h3>Segments in Detail</h3>
The company conducts its operations through two reportable segments &mdash; North American OTC Healthcare and International OTC Healthcare.
Revenues in the North American OTC Healthcare segment totaled $231.1 million, down 4.6% from the year-earlier quarter. Our model projected the segment&#39;s revenues to be $242.6 million in the fourth quarter.
The revenue performance for the quarter was due to the inability to supply customer orders late in the quarter in certain brands as well as a lower Women&#39;s Health category and the strategic exit of private label business.
Revenues in the International OTC Healthcare segment were $45.9 million, up 5.3% from the year-ago quarter&#39;s figure. The company reported strong performance across numerous brands and geographies. However, this was marred by poor supply chain constraints.
Our model projected revenues from this segment to be $44.4 million.
<div class="chart_embed">
<h3>Prestige Consumer Healthcare Inc. Price, Consensus and EPS Surprise</h3>
<a href="https://www.zacks.com/stock/chart/PBH/price-consensus-eps-surprise-chart?icid=chart-PBH-price-consensus-eps-surprise-chart"><img alt="Prestige Consumer Healthcare Inc. Price, Consensus and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/65/1715868484.png" style="height:265px; width:577px" title="" /> </a>
Prestige Consumer Healthcare Inc. price-consensus-eps-surprise-chart | Prestige Consumer Healthcare Inc. Quote
</div>
<h3>Margins</h3>
The gross profit in the fiscal fourth quarter declined 1.1% year over year to $153.9 million.&nbsp; Meanwhile, the gross margin expanded 115 basis points (bps) year over year to 55.6% on a 5.6% increase in the cost of sales (excluding depreciation).
During the quarter, advertising and marketing expenses rose 21.5% to $37.5 million, while general and administrative expenses decreased 4.3% to $26.5 million. Adjusted operating income in the quarter under review was $89.9 million, highlighting a decrease of 7.3%. The adjusted operating margin contracted 147 bps to 32.5%.
<h3>Financial Update</h3>
Prestige Consumer exited the fiscal fourth quarter with cash and cash equivalents of $46.5 million compared with the $63.6 million recorded at the end of the fiscal third quarter. Long-term debt totaled $1.13 billion, down from $1.20 billion at the end of fiscal third quarter.
The cumulative net cash provided by operating activities at fourth-quarter end was $248.9 million compared with $229.7 million in the year-ago period. The cumulative adjusted free cash flow at the end of the fiscal fourth quarter was $239.4 million compared with $221.9 million in the year-ago period.
<h3>Guidance</h3>
The company provided its initial fiscal 2025 organic revenue growth and EPS outlook.
Revenues for the full year are anticipated in the range of $1.125 billion-$1.140 billion. Organic revenue growth for the full year is anticipated to be approximately 1%. The Zacks Consensus Estimate for fiscal 2025 revenues is pegged at $1.16 billion.
Prestige Consumer expects fiscal 2025 EPS to be in the range of $4.40-$4.46. The Zacks Consensus Estimate for fiscal 2025 EPS stands at $4.61.
Free cash flow for the full year is likely to be $240 million or more.
<h3>Our Take</h3>
PBH exited the fiscal fourth quarter of 2024 with lower-than-expected revenues and earnings. &nbsp;The company noted that strong consumption trends and organic international segment growth were more than offset by supply chain pressure as well as continued Women&#39;s Health category weakness and the strategic exit of the private label business.Within the North American OTC segment, headwinds related to the strategic exit of the private-label business and weakness in certain non-core brands marred the strength of the Eye and Ear Care category.
The contraction of the adjusted operating margin during the quarter is discouraging.
<h3>Zacks Rank and Key Picks</h3>
Prestige Consumer currently carries a Zacks Rank #3 (Hold).
Some top-ranked stocks from the broader medical space are Medpace (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/medp#NASDAQ">MEDP</a>), ResMed (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rmd#NYSE">RMD</a>) and Encompass Health Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ehc#NYSE">EHC</a>).
Medpace, sporting a Zacks Rank #1 (Strong Buy), reported first-quarter 2024 EPS of $3.20, which beat the Zacks Consensus Estimate by 30.6%. Revenues of $511 million improved 17.7% from last year&#39;s comparable figure.
Medpace has an estimated 2024 earnings growth rate of 26.5% compared with the industry&#39;s 12.3%. The company&#39;s earnings surpassed estimates in each of the trailing four quarters, the average being 12.8%.
ResMed, carrying a Zacks Rank #2 (Buy), reported first-quarter 2024 EPS of $2.13, which topped the Zacks Consensus Estimate by 10.9%. Revenues of $1.20 billion surpassed the Zacks Consensus Estimate by 1.9%.
RMD has an estimated fiscal 2024 earnings growth rate of 17.9% compared with the industry&#39;s 15.7%. The company delivered a four-quarter average earnings surprise of 2.8%.
Encompass Health, carrying a Zacks Rank #2, reported first-quarter 2024 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 20.4%. Net operating revenues of $1.3 billion topped the Zacks Consensus Estimate by 3.6%.
EHC has an estimated long-term earnings growth rate of 15.6% compared with the industry&#39;s 11.7% growth. The company&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.7%.
<a href="https://www.zacks.com/stock/news/2274934/prestige-consumer-pbh-q4-earnings-miss-operating-margin-falls?cid=CS-BENZ-FT-analyst_blog|earnings_article-2274934">To read this article on Zacks.com click here.</a>

Earnings Misses

MEDP

Prestige Consumer Q4 Earnings Miss, Operating Margin Falls

DA Davidson analyst Linda Bolton Weiser maintains Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) with a Neutral and maintains $65 price target.

DA Davidson Maintains Neutral on Prestige Consumer, Maintains $65 Price Target

WIIM

Prestige Consumer shares are trading lower after the company reported worse-than-expected Q4 financial results and issued weak guidance.

With U.S. stock futures trading mixed this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) to report quarterly earnings at 82 cents per share on revenue of $12.53 billion after the closing bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Cisco shares rose 0.1% to $49.00 in after-hours trading.</li>
<li>Prestige Consumer Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) reported worse-than-expected financial results for the fourth quarter and issued weak guidance. Prestige Consumer Healthcare shares dipped 7.7% to $66.00 in the after-hours trading session.</li>
<li>Analysts are expecting Arcos Dorados Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARCO#NYSE">ARCO</a>) to post quarterly earnings at 17 cents per share on revenue of $1.02 billion. The company will release earnings before the markets open. Arcos Dorados shares rose 1.7% to $11.40 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a> 
<ul>
<li>Infinera Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INFN#NASDAQ">INFN</a>) reported weak preliminary financial results for the first quarter. The company said it sees preliminary adjusted loss of 17 cents per share, versus market expectations for a loss of 13 cents per share. It expects preliminary revenue of $306.9 million for the quarter, down from estimates of $336.995 million. Infinera shares tumbled 10.8% to $5.17 in the after-hours trading session.</li>
<li>Analysts expect Dole plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOLE#NYSE">DOLE</a>) to post quarterly earnings at 31 cents per share on revenue of $2.12 billion before the opening bell. Dole shares rose 1.2% to $12.41 in after-hours trading.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/24/05/38817342/jim-cramer-says-nu-skin-is-overvalued-praises-fabulous-pure-storage">Jim Cramer Says Nu Skin Is &#8216;Overvalued,&#8217; Praises &#8216;Fabulous&#8217; Pure Storage</a>

Pre-Market Outlook

ARCO

CSCO

DOLE

INFN

Cisco, Prestige Consumer Healthcare And 3 Stocks To Watch Heading Into Wednesday

Buybacks

Prestige Consumer Healthcare On May 6 Authorized Repurchase Of Up To $300M

Prestige Consumer Healthcare Sees FY25 Revenue Growth ~1%, EPS $4.40-$4.46 vs $4.62 Est.

Prestige Consumer Healthcare beats top-line and bottom-line estimates; reaffirms FY24 outlook

Prestige Consumer Healthcare Inc. 2025 Q1 - Results - Earnings Call Presentation

Prestige Consumer Healthcare Inc. (PBH) Q2 2024 Earnings Call Transcript

Tracking John Rogers' Ariel Investments Portfolio - Q2 2024 Update

Analyst Susan Anderson from Canaccord Genuity maintained a Buy rating on Prestige Consumer Healthcare (PBH – Research Report) and keeping the price...

Prestige Consumer Healthcare: A Strong Buy on Brand Resilience and Strategic Growth Opportunities

Prestige Consumer Healthcare Non-GAAP EPS of $1.09 beats by $0.01, revenue of $283.8M beats by $0.98M

Prestige Consumer Healthcare ( ($PBH) ) has issued an announcement. Prestige Consumer Healthcare Inc. surpassed expectations in Q2 of fiscal 2025 w...

Prestige Consumer Healthcare Exceeds Q2 2025 Expectations

Prestige Consumer Healthcare ( ($PBH) ) has released its Q2 earnings. Here is a breakdown of the information Prestige Consumer Healthcare presented...

Prestige Consumer Healthcare Reports Robust Q2 FY25 Results

Prestige Consumer Healthcare Inc (PBH) Q2 2025 Earnings Call Transcript

D.A. Davidson analyst Linda Bolton Weiser maintained a Buy rating on Prestige Consumer Healthcare (PBH – Research Report) today. The company's shar...

D.A. Davidson Sticks to Their Buy Rating for Prestige Consumer Healthcare (PBH)

APTV

ATGE

BAIDF

BIDU

BOKF

CHKP

GILD

GNRC

GNTX

MGRB

MGRD

MGRE

MSFT

MSGE

NTRS

NTRSO

PARA

PARAA

REZI

SAEF

SPHR

ZBRA

Press Releases

Prestige Consumer Healthcare Inc. Reports Third Quarter Fiscal 2024 Results

General

Dramamine® Celebrates its 75th Anniversary by Reviving an Unexpected Partner: The Barf Bag

Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Fourth Quarter and Year-End Earnings Results

Prestige Consumer Healthcare Inc. Reports Fiscal Year 2024 Results

Prestige Consumer Healthcare Inc. to Present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference

Prestige Consumer Healthcare to Release Fiscal 2025 First Quarter Earnings Results

Prestige Consumer Healthcare Inc. Reports First Quarter Fiscal 2025 Results

Prestige Consumer Healthcare to Present at the Barclays Global Consumer Staples Conference

Prestige Consumer Healthcare to Release Fiscal 2025 Second Quarter Earnings Results

Prestige Consumer Healthcare Inc. Reports Second Quarter and First Half Fiscal 2025 Results

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Prestige Consumer

Notizie

Ultime notizie per Prestige Consumer (NYSE:PBH) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO